Part of the
Stem Cell Revolution

Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.

Technology

NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
Read more

ProTrans shows significant effect in Diabetes

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
Sample in a lab is being examinedRead more

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
Read more
Cover art of NextCell report
Read our latest report:
Interim Report Q2 2021/2022
Download

News

2022-04-28

NextCell Pharma publishes Interim Report 2 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M
Read moreRead more
2022-04-26

NextCell is attending a conference for worldleading celltherapies

NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t
Read moreRead more
2022-04-07

First age group treated in paediatric diabetes study with ProTrans

NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.
Read moreRead more
2022-04-01

Cellaviva delivers stem cells to treat serious blood disease

NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.
Read moreRead more
All news